Updates from AASLD 2025 | April 1, 2026
Date of Presentation: April 1, 2026
Type: Past Presentation
Program: Hepatitis C
Keywords: #daa #dementia #drug induced liver injury #encephalopathy #hcv #sofosbuvir #velpatasvir #voxilaprevir
In this presentation, Dr. Paulina Deming, PharmD, PhC, reviews common causes of drug induced liver injury (DILI) in adults, identifies the overlap between hepatic encephalopathy and dementia and discusses emerging data in assessing SVR for patients with prior DAA treatment failure treated with sofosbuvir/velpatasvir/voxilaprevir.
Presented by:
Dr. Paulina Deming
Dr. Paulina Deming is an Associate Professor-Clinical Educator within the Pharmacy Practice and Administrative Sciences Department at the College of Pharmacy at the University of New Mexico Health Sciences Center (UNMHSC). Dr. Deming completed a general practice residency and infectious diseases pharmacotherapy residency at UNMHSC. Her interests are focused in hepatitis C virus (HCV) infections and clinical therapeutics. She is the assistant director for the Project ECHO (Extension for Community Healthcare Outcomes) HCV clinic and serves on Project ECHO’s expert faculty panel advising providers on HCV care in community, corrections, and within the Indian Health Services settings. Licensed as a pharmacist clinician, she sees patients through the UNMHSC’s HCV clinic and the Truman HCV-HIV coinfection clinic. In addition to teaching and clinical work, Dr. Deming has co-authored papers on the management of HCV infections as well as HCV treatment outcomes in real-world settings.
Read the full bio …Resources Provided:
Date added: March 24, 2026











































